DelveInsight has launched a new report on Soft Tissue Sarcoma with Lung Metastasis Epidemiology
Soft tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas).
Soft Tissue Sarcoma with Lung Metastasis Epidemiology and Changing Market Dynamics of Soft tissue sarcoma with lung metastasis in the Seven Major Markets
Once the systemic metastatic disease develops, the prognosis is typically poor. Patients with extremity sarcomas are more likely to develop the distant metastatic disease as the initial site of recurrence. In contrast, those with retroperitoneal and visceral sarcomas tend to present local recurrence. The lung is the most frequent site of metastasis from soft-tissue sarcomas. Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of pulmonary metastases has been a pivotal therapy in this disease.
Key facts of Soft Tissue Sarcoma with Lung Metastasis Epidemiology
As per the study conducted by Digesu et al. (2016), sarcoma comprises a heterogeneous group of histologic subtypes with a propensity to metastasize to the lungs. Isolated pulmonary metastases occur in as many as 20% of patients diagnosed with soft tissue sarcoma and as many as 40% in those with primary bone sarcoma.
According to the study conducted by Lindsay et al. (2018), soft tissue and bone sarcomas represent less than 1% of all malignancies diagnosed in the United States annually. The most common site of metastasis is the lung, with metastatic pulmonary disease occurring in 19–50% of patients.
According to a study conducted by Lindwer et al. (2018), there were slightly more males (53.4%) patients with lung lesions only, as compared to females (46.6%).
Soft Tissue Sarcoma with Lung Metastasis Epidemiology Segmentation
Total Incident Cases of STS in the 7MM [2017–2030]
Total Incident Cases of STS with lung metastasis in the 7MM [2017–2030]
Gender-specific Incidence of STS with lung metastasis in the 7MM [2017–2030]
Treatable Cases of STS with lung metastasis in the 7MM (2017–2030)
Soft Tissue Sarcoma with Lung Metastasis Epidemiology Report Scope
The report covers the descriptive overview of STS with lung metastases, explaining its causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of STS with lung metastases.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases.
Request for free sample copy– https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-lung-metastases-epidemiology-forecast
Table of content
1 Key Insights
2 Executive Summary of STS with lung metastases
3 Disease Background and Overview: STS with lung metastases
4 Epidemiology and Patient Population
5 United States Epidemiology
6 EU5 Epidemiology
7 Japan Epidemiology
9 DelveInsight Capabilities
11 About DelveInsight
What will be the Key Questions Answered?
What is the disease risk, burden, and unmet needs of STS with lung metastases?
What is the historical STS with lung metastases patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of STS with lung metastases at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to STS with lung metastases?
Out of the above-mentioned countries, which country would have the highest incident population of STS with lung metastases during the forecast period (2020–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Why should you buy this report?
The STS with lung metastases report will allow the user to –
Develop business strategies by understanding the trends shaping and driving the 7MM STS with lung metastases epidemiology forecast.
The STS with lung metastases epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The STS with lung metastases epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States